文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症谵妄抗精神病药治疗后的长期结局(MIND-USA):随机、安慰剂对照、3期试验

Long-term outcomes after treatment of delirium during critical illness with antipsychotics (MIND-USA): a randomised, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2024-04-30
一句话结论对重症谵妄患者,氟哌啶醇或齐拉西酮未改善幸存者3个月和12个月认知、功能、心理或生活质量结局,作者认为不应常规用于治疗重症成人谵妄。

MIND-USA长期随访在16家美国医院纳入因呼吸衰竭或脓毒性/心源性休克入住ICU且存在谵妄的成人,按1:1:1随机接受静脉安慰剂、氟哌啶醇或齐拉西酮最多14天,于随机后3个月和12个月评估幸存者认知、功能、心理、生活质量与就业结局。三组认知损害均常见,各治疗组3个月和12个月随访时均有三分之一幸存者存在认知损害,各组超过半数受访幸存者存在认知或躯体限制(或两者兼有)而无法就业。与安慰剂相比,氟哌啶醇和齐拉西酮在3个月和12个月均未显著改变以电话认知状态访谈T评分衡量的认知结局,也未发现功能、心理、生活质量或就业结局改善的证据。作者认为抗精神病药不应常规用于治疗重症成人谵妄。

要点

  • 与安慰剂相比,氟哌啶醇3个月认知结局校正OR 1.22(95%CI 0.73-2.04)、12个月1.12(95%CI 0.60-2.11),均未达统计学显著。
  • 与安慰剂相比,齐拉西酮3个月认知结局校正OR 1.07(95%CI 0.59-1.96)、12个月0.94(95%CI 0.62-1.44),均未达统计学显著。
  • 三组认知损害均常见,各治疗组3个月和12个月随访时均有三分之一幸存者存在认知损害。
  • 各组超过半数受访幸存者在3个月和12个月均存在认知或躯体限制(或两者兼有)而无法就业。
  • 作者认为,结合短期获益证据不足及出院时抗精神病药常被不恰当继续使用,抗精神病药不应常规用于治疗重症成人谵妄。

适用人群与场景

  • 年龄≥18岁、因呼吸衰竭或脓毒性或心源性休克入住ICU且存在谵妄的成人。

处置流程与药物剂量

  • 随机1:1:1接受静脉安慰剂、氟哌啶醇或齐拉西酮,最多14天。

研究设计与关键结果

  • 研究类型:随机、双盲、安慰剂对照3期MIND-USA研究的预设长期随访,在美国16家医院开展。
  • 2011年12月7日至2017年8月12日筛查20 914人,566例符合条件并同意或由他人代为同意参与;安慰剂组184例、氟哌啶醇组192例、齐拉西酮组190例。
  • 1年生存率和随访率组间相似。
  • 认知损害在三组均常见,各治疗组3个月和12个月随访时均有三分之一幸存者存在认知损害。
  • 各组超过半数受访幸存者在3个月和12个月均存在认知或躯体限制(或两者兼有)而无法就业。
  • 与安慰剂相比,氟哌啶醇未显著改变以电话认知状态访谈T评分衡量的认知结局:3个月校正OR 1.22(95%CI 0.73-2.04),12个月校正OR 1.12(95%CI 0.60-2.11)。
  • 与安慰剂相比,齐拉西酮未显著改变以电话认知状态访谈T评分衡量的认知结局:3个月校正OR 1.07(95%CI 0.59-1.96),12个月校正OR 0.94(95%CI 0.62-1.44)。
  • 未发现与安慰剂相比氟哌啶醇或齐拉西酮改善功能、心理、生活质量或就业结局的证据。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照3期试验的预设长期随访。
  • 作者结论:氟哌啶醇和齐拉西酮对幸存者认知、功能、心理或生活质量结局均无显著影响;结合短期获益证据不足及出院时抗精神病药常被不恰当继续使用,抗精神病药不应常规用于治疗重症成人谵妄。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,抗精神病药不应常规用于治疗重症成人谵妄。
  • 作者指出短期获益证据不足,且出院时抗精神病药常被不恰当地继续使用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Delirium is common during critical illness and is associated with long-term cognitive impairment and disability. Antipsychotics are frequently used to treat delirium, but their effects on long-term outcomes are unknown. We aimed to investigate the effects of antipsychotic treatment of delirious, critically ill patients on long-term cognitive, functional, psychological, and quality-of-life outcomes.

METHODS: This prespecified, long-term follow-up to the randomised, double-blind, placebo-controlled phase 3 MIND-USA Study was conducted in 16 hospitals throughout the USA. Adults (aged ≥18 years) who had been admitted to an intensive care unit with respiratory failure or septic or cardiogenic shock were eligible for inclusion in the study if they had delirium. Participants were randomly assigned-using a computer-generated, permuted-block randomisation scheme with stratification by trial site and age-in a 1:1:1 ratio to receive intravenous placebo, haloperidol, or ziprasidone for up to 14 days. Investigators and participants were masked to treatment group assignment. 3 months and 12 months after randomisation, we assessed survivors' cognitive, functional, psychological, quality-of-life, and employment outcomes using validated telephone-administered tests and questionnaires. This trial was registered with ClinicalTrials.gov, NCT01211522, and is complete.

FINDINGS: Between Dec 7, 2011, and Aug 12, 2017, we screened 20 914 individuals, of whom 566 were eligible and consented or had consent provided to participate. Of these 566 patients, 184 were assigned to the placebo group, 192 to the haloperidol group, and 190 to the ziprasidone group. 1-year survival and follow-up rates were similar between groups. Cognitive impairment was common in all three treatment groups, with a third of survivors impaired at both 3-month and 12-month follow-up in all groups. More than half of the surveyed survivors in each group had cognitive or physical limitations (or both) that precluded employment at both 3-month and 12-month follow-up. At both 3 months and 12 months, neither haloperidol (adjusted odds ratio 1·22 [95% CI 0·73-2.04] at 3 months and 1·12 [0·60-2·11] at 12 months) nor ziprasidone (1·07 [0·59-1·96] at 3 months and 0·94 [0·62-1·44] at 12 months) significantly altered cognitive outcomes, as measured by the Telephone Interview for Cognitive Status T score, compared with placebo. We also found no evidence that functional, psychological, quality-of-life, or employment outcomes improved with haloperidol or ziprasidone compared with placebo.

INTERPRETATION: In delirious, critically ill patients, neither haloperidol nor ziprasidone had a significant effect on cognitive, functional, psychological, or quality-of-life outcomes among survivors. Our findings, along with insufficient evidence of short-term benefit and frequent inappropriate continuation of antipsychotics at hospital discharge, indicate that antipsychotics should not be used routinely to treat delirium in critically ill adults.

FUNDING: National Institutes of Health and the US Department of Veterans Affairs.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Mart MF, Boehm LM, Kiehl AL, et al. Long-term outcomes after treatment of delirium during critical illness with antipsychotics (MIND-USA): a randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2024. PMID: 38701817. doi:10.1016/S2213-2600(24)00077-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。